US Court Rules Against Lupin In Mirabegron Patent Case

Lupin Ltd. announced late Wednesday that a US district court has ruled against the company in a patent infringement case concerning its generic version of Mirabegron, a medication used to treat overactive bladder symptoms.

The District Court of Delaware upheld the validity of the patent owned by Astellas Pharma Inc. Lupin stated that issues related to damages and additional invalidity arguments will be addressed during a consolidated jury trial scheduled for 2026.

“At this stage, based on the court's order, there are no material financial implications. Lupin remains confident in its legal position and is currently evaluating further legal options." the company added it its exchange filing.